CASI Pharmaceuticals, Inc. Sample Contracts
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • December 20th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
INDEMNIFICATION AGREEMENTIndemnification Agreement • January 31st, 2023 • CASI Pharmaceuticals Holdings, Inc.
This INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of by and between CASI Pharmaceuticals, Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”), and , an individual (Passport/ID Card No. ) (the “Indemnitee”).
Guarantee ContractGuarantee Contract • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • Macau
This Guarantee Contract (this “Contract”) is entered into this 14th day of December 2023 in Huishan District, Wuxi City, Jiangsu Province, China, by and among the following parties:
SUBSCRIPTION AGREEMENTSubscription Agreement • August 16th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
The Company, on the one hand, and the Purchaser, on the other hand, are hereinafter each referred to as a “Party” and collectively as the “Parties”.
ContractExclusive Distribution Agreement • April 26th, 2023 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations
Certain confidential information contained in this document, marked by brackets and *** asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed.
CASI PHARMACEUTICALS, INC. CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENTConvertible Promissory Note Purchase Agreement • May 15th, 2026 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “Purchase Agreement”) is dated as of December 9, 2025 (the “Effective Date”), by and between CASI Pharmaceuticals, Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and ETP Global III Fund LP, a Delaware limited partnership (the “Purchaser”).
ContractExclusive Distribution Agreement • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations
Information in this exhibit identified by brackets and *** has been redacted because it is not material and is the type that the Company treats as private or confidential
Equity and Asset Transfer Agreement By and Among CASI Pharmaceuticals, Inc. Kaixin Pharmaceuticals Inc. CASI Pharmaceuticals (China) Co., Ltd. AND CASI Pharmaceuticals (Wuxi) Co., Ltd. May 9, 2025Equity and Asset Transfer Agreement • May 15th, 2026 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations
This Equity and Asset Transfer Agreement (this “Agreement”) is entered into on May 9, 2025 (the “Execution Date”) in the People’s Republic of China (the “PRC”) by and among:
Capital Reduction Agreement CASI Pharmaceuticals (Wuxi) Co., Ltd. Wuxi, China December 14, 2023Capital Reduction Agreement • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations
This Capital Reduction Agreement of CASI Pharmaceuticals (Wuxi) Co., Ltd. (this “Agreement”) is entered into this 14th day of December 2023 (“Signing Date”) in Huishan District, Wuxi City, Jiangsu Province, China, by and among the following parties:
AMENDMENT NO. 1 TO Assignment AGREEMENT IN RESPECT OF THE TERRITORY OF CHINAAssignment Agreement • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment 1”) is hereby entered into as of July 31, 2023 (“Amendment 1 Effective Date”) by and between Acrotech Biopharma Inc. (“Acrotech”), having a principal place of business at 279 Princeton Hightstown Road, Suite 103, East Windsor, New Jersey 08520, and CASI Pharmaceuticals, Inc. (“CASI”), having a principal place of business at 1701-1702, China Central Office, Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing 100025 People’s Republic of China (collectively, the “Parties”).
SUBSCRIPTION AND PURCHASE AGREEMENTSubscription and Purchase Agreement • August 16th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
The Company, on the one hand, and the Purchaser, on the other hand, are hereinafter each referred to as a “Party” and collectively as the “Parties”.
SUBSCRIPTION AND PURCHASE AGREEMENTSubscription and Purchase Agreement • August 16th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
The Company, on the one hand, and each Purchaser, on the other hand, are hereinafter each referred to as a “Party” and collectively as the “Parties”.
1Information in this exhibit identified by brackets and *** has been redacted because it is not material and is the type that the Company treats as private or confidentialAssignment Agreement • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
FOLOTYN SUPPLY AGREEMENTSupply Agreement • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This FOLOTYN SUPPLY AGREEMENT (this “Agreement”), dated as of July 31, 2023 (the “Effective Date”), is made between Acrotech Biopharma Inc., a State of Delaware corporation (“Acrotech” or “Supplier”), with offices at 279 Princeton-Hightstown Road, Suite 103, East Windsor, NJ 08520, and CASI Pharmaceuticals, Inc., a Cayman corporation (“CASI” or “Buyer”), with offices at 1701-1702, China Central Office, Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing 100025 People’s Republic of China. Supplier and Buyer are referred to as the “Parties.”
SUPPLEMENTARY AGREEMENT TO THE EXCLUSIVE DISTRIBUTION AGREEMENTSupplementary Agreement to the Exclusive Distribution Agreement • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations
This Supplementary Agreement to the Exclusive Distribution Agreement (this “Supplementary Agreement”), is entered into as of 【28】February, 2024(“Effective Date”), by and between:
Equity Transfer AgreementEquity Transfer Agreement • May 15th, 2026 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations
Party A: Wuxi Zhihe Daokang II Venture Capital Partnership (Limited Partnership) (hereinafter referred to as “Zhihe Daokang” or the “Transferor”), a limited partnership legally established and validly existing under the laws of the People’s Republic of China, with Unified Social Credit Code 91320205MA27GJLN83.
EXECUTION VERSIONAssignment of Rights Agreement • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations
Information in this exhibit identified by brackets and *** has been redacted because it is not material and is the type that the Company treats as private or confidential
Form EMPLOYMENT AGREEMENTEmployment Agreement • January 31st, 2023 • CASI Pharmaceuticals Holdings, Inc.
This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of [*], by and between CASI PHARMACEUTICALS, INC., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”), and [*] (the “Executive”).
ContractAssignment Agreement • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Information in this exhibit identified by brackets and *** has been redacted because it is not material and is the type that the Company treats as private or confidential
Convertible Loan Agreement in respect of CASI Pharmaceuticals (Wuxi) Co., Ltd. by and among Wuxi Huicheng Yuanda Investment Partnership (Limited Partnership) on the one hand - and - CASI Pharmaceuticals (Wuxi) Co., Ltd. CASI Pharmaceuticals, Inc. CASI...Convertible Loan Agreement • March 28th, 2024 • CASI Pharmaceuticals, Inc. • Pharmaceutical preparations
This Convertible Loan Agreement in respect of CASI Pharmaceuticals (Wuxi) Co., Ltd. (this “Agreement” or “Convertible Loan Agreement”) is entered into this 14th day of December 2023 (“Signing Date”) in Huishan District, Wuxi City, Jiangsu Province, China, by and among the following parties: